ELEVATED SERUM PENTRAXIN-3 LEVELS IS POSITIVELY CORRELATED TO DISEASE SEVERITY AND COAGULOPATHY IN COVID-19 PATIENTS

Abstract

Abstract BACKGROUND Coronavirus disease 2019 (COVID-19) is highly contagious and deadly and is associated with coagulopathy. Pentraxin-3(PTX3) participates in innate resistance to infections and plays a role in thrombogenesis. PURPOSE The present study aimed to investigate the role of PTX3 in coagulopathy in patients with COVID-19. METHODS A retrospective study including thirty-nine COVID-19 patients enrolled in Hunan, China were performed. The patients were classified into the D-dimer_L (D-dimer?1mg/L) and D-dimer_H (D-dimer?1mg/L) groups basing on the plasma D-dimer levels on admission. Serum PTX3 levels were detected by enzyme-linked immunosorbent assays and compared between those two groups, and then linear regression models were applied to analyze the association between PTX3 and D-dimer. RESULTS Our results showed that serum PTX3 levels (median values, 10.21 vs 3.36, P < 0.001), chest computerized tomography scores (median values, 10.0 vs 9.0, P < 0.05), and length of stay (16.0±4.2 vs 10.7±3.6, P = 0.001) in the D-dimer_H group were significantly higher than that in D-dimer_L group. The coefficient of determination for PTX3 was 0.651 (P < 0.001) in the D-dimer_H group. CONCLUSION Serum level of PTX3 was positively correlated with disease severity and coagulopathy. Detection of serum PTX3 level could assist to identify severer patients on admission and may be a potential therapeutic target for coagulopathy in patients with COVID-19.